Previous Article | Next Article ![]()
Molecular and Cellular Biology, October 2003, p. 7055-7067, Vol. 23, No. 19
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.19.7055-7067.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
CP2-Containing RNP Complexes
Departments of Genetics and Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Received 12 March 2003/ Returned for modification 10 June 2003/ Accepted 1 July 2003
|
|
|---|
-globin poly(C) binding proteins (
CPs) comprise a highly abundant subset of K homology (KH) domain RNA binding proteins and have a characteristic preference for binding single-stranded C-rich motifs.
CPs have been implicated in translation control and stabilization of multiple cellular and viral mRNAs. To explore the full contribution of
CPs to cell function, we have identified a set of mRNAs that associate in vivo with the major
CP2 isoforms. One hundred sixty mRNA species were consistently identified in three independent analyses of
CP2-RNP complexes immunopurified from a human hematopoietic cell line (K562). These mRNAs could be grouped into subsets encoding cytoskeletal components, transcription factors, proto-oncogenes, and cell signaling factors. Two mRNAs were linked to ceroid lipofuscinosis, indicating a potential role for
CP2 in this infantile neurodegenerative disease. Surprisingly,
CP2 mRNA itself was represented in
CP2-RNP complexes, suggesting autoregulatory control of
CP2 expression. In vitro analyses of representative target mRNAs confirmed direct binding of
CP2 within their 3' untranslated regions. These data expand the list of mRNAs that associate with
CP2 in vivo and establish a foundation for modeling its role in coordinating pathways of posttranscriptional gene regulation. |
|
|---|
Limited examples of coordinate control by RNA binding proteins can be cited from the literature. An initial example is represented by the iron response element binding protein (8). This iron-binding protein can reversibly block translation of ferritin mRNA via 5' untranslated region (UTR) binding and reversibly stabilize transferrin receptor mRNA via 3' UTR binding. These distinct actions of the iron response element binding protein coordinate an integrated cellular response to intracellular iron levels. By defining the full-spectrum target mRNAs for specific RNA binding proteins, it may be possible to define even more complex posttranscriptional control networks. Recent examples are the identification of subsets of mRNAs bound by the K homology (KH)-domain fragile X mental retardation protein (5) and segregation of nuclear mRNAs into distinct sets of RNPs during nuclear-cytoplasmic export (17). The concept of coordinate control of multiple genes by RNA-binding proteins has been recently proposed in terms of posttranscriptional operons (21).
The
-globin poly(C) binding proteins (
CPs), also known as hnRNP E (34) or poly(C) binding proteins (PCBP) (1, 23, 24), comprise a family of highly abundant and widely expressed RNA binding proteins. Multiple
CP isoforms are encoded by four dispersed paralogous loci (29, 31, 32, 48). The two most abundant and widely expressed of these proteins,
CP2 and
CP2-KL, are encoded by alternative splicing of the
CP2 transcript (10).
CPs are conserved across several genera: orthologues of
CPs are found in Xenopus laevis, Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces cerevisiae (32). The abundant expression, widespread tissue distribution (24, 29, 31), and evolutionary conservation of
CPs suggest that they serve fundamental functions.
Each
CP isoform contains a characteristic triple repeat of the 70-amino-acid heteronuclear ribonucleoprotein (hnRNP) KH domain. The KH domain is common to a wide spectrum of RNA binding proteins (13) and can interact via a molecular vise with four to five contiguous bases in a target RNA (25, 26). Since KH domains can interact independently with RNA sequences, arrays of such motifs in a protein can generate substantial complexity and specificity of RNA interactions.
CPs have a characteristic preference for binding to single-stranded C-rich motifs, and binding to these elements has been linked to a number of posttranscriptional controls (2, 12, 35, 36, 38, 45, 52, 53). The initial function defined for
CPs was stabilization of human
2-globin (
-globin) mRNA (6, 23, 52, 53) via binding to a 3' UTR C-rich motif (52).
CP1 and
CP2 have also been linked to stabilization of
1(I) collagen and tyrosine hydroxylase mRNAs via interacting with respective C-rich 3' UTR motifs (38, 45). Based on these and other studies (9, 55), it has been proposed that the complex between
CP and the cis-acting stability elements, referred to as the
-complex (52), constitutes a general determinant of high-level mRNA stability (18).
In addition to its role in mRNA stabilization,
CP also functions in a range of translation controls. Binding of
CP1 and hnRNP K to the 3' UTR of 15-lipoxygenase mRNA maintains the mRNA in a translationally silent state until the final stages of erythroid differentiation (35).
CP2-mediated translational control also appears to be involved in the pathological block in CCAAT/enhancer binding protein
(c/EBP
) expression in myelogenous leukemia via binding to a C-rich intercistronic motif (39).
CPs can also facilitate translation of cellular mRNAs. For example, translational activation is mediated by binding of
CP to the 5' UTR of the folate receptor
mRNA (54) and binding to a 3' UTR C-rich motif in the phosphatase 2A mRNA (36).
CPs bind to several viral mRNAs, and the corresponding RNP complexes are involved in many aspects of the viral life cycle (3, 4, 7, 11, 12, 14, 16, 33, 37, 44, 51). Several of these studies indicate that functional interactions may be specific for particular
CP isoforms, may work in conjunction with additional RNA binding proteins, and may be impacted by cellular differentiation (7, 35).
Five mRNAs have been identified in a screen for
CP1 binding targets: mitochondrial NADH dehydrogenase subunit 3, mitochondrial cytochrome c oxidase subunit II (coxII), ribosomal protein of the large subunit (L27a), palmitoylated erythrocyte membrane protein p55, manganese superoxide dismutase, and the CD81 receptor (TAPA-1) (49). The mRNAs encoding TAPA-1 and coxII were further shown to contain
CP1 binding sites in the 3' UTRs by in vitro binding assays. It is unknown whether these mRNAs constitute
CP1 binding targets in vivo, and the function of these
CP1-RNP complexes remains undefined.
The variety of
CP targets and control mechanisms suggests that the
CP-RNP complexes play significant and multifaceted roles in gene expression. Identification of additional mRNA targets would facilitate further exploration of this potential. In this study, we have attempted to identify a spectrum of in vivo binding targets of the major
CP2 isoforms by microarray analysis of immunopurified cytoplasmic
CP2-RNPs. Three independent studies revealed that 160 mRNAs were specifically and reproducibly present in the
CP2-RNP complexes. These data expand the list of
CP2 binding mRNAs and suggest targets for subsequent studies of potential coordinated cell functions.
|
|
|---|
RNP IP.
Protein A-Sepharose (PAS) (Amersham) was washed three times in PBS (Invitrogen) at room temperature. Two hundred microliters of a 50% slurry of PAS and PBS was incubated with 5 µl of FF3 (anti-
CP2 and
CP2-KL) or anti-c-myc (Santa Cruz) antibodies in the presence of 0.35 U of anti-RNase/µl (Ambion) in PBS in a volume of 1.0 ml. The FF3 immunoprecipitates (IPs) are referred to as anti-
CP2, and the c-myc IPs are referred to as control. The mixtures were incubated for 1 h at 4°C, and the PAS was washed once with PBS. The K562 cytoplasmic extract (2.1 mg/IP) was centrifuged at 11,750 x g for 10 min at 4°C. The supernatant was diluted fourfold in binding buffer (BB) (20 mM HEPES [pH 7.9] and 150 mM NaCl) containing 0.05% Triton X-100. Anti-RNase (Ambion) was added to 0.15 U/µl. This extract was added to the PAS, incubated for 1 h at 4°C, and washed twice in BB containing 0.05% Triton X-100, followed by two washes in BB containing 1% Triton X-100. The PAS was resuspended in BB containing 0.05% Triton X-100, and the suspension was transferred to a fresh tube. The PAS was pelleted and resuspended in elution buffer (100 mM Tris-HCl [pH 7.4], 12.5 mM EDTA, 150 mM NaCl, and 1% sodium dodecyl sulfate [SDS]). The mixture was incubated for 3 min at 100°C, phenol extracted, ethanol precipitated with glycogen (20 µg; Boehringer), and resuspended in 20 µl of H2O.
Reverse transcription-PCR.
Copurified RNA (1.5 µl) was incubated with 1 pmol of reverse primer (listed in Table 1), 1 mM each dNTPs, 2.5 U of anti-RNase (Ambion), 50 U of Moloney murine leukemia virus reverse transcriptase (Promega), and 1x Moloney murine leukemia virus reverse transcription (RT) buffer (Promega) in a volume of 12.5 µl. After incubation at 37°C for 1 h, the samples were used as a template for PCR. The PCR primers are listed in Table 1. The forward primer (8 pmol) was end labeled by incubation with 5 µl of [
-32P]rATP (6,000 Ci/mmol), 1x forward reaction buffer (Gibco), and 10 U of T4 polynucleotide kinase (Gibco) for 30 min at 37°C and at 65°C for 10 min. The PCRs included 5 µl of the RT product, 0.2 mM dNTPs, 1.5 mM MgCl2, 2.5 µl of the labeled primer, 2.5 µg of each primer, 0.25 U of AmpliTaq (Perkin Elmer), and 1x PCR buffer II (Perkin Elmer). Thermocycler conditions were 95°C for 3 min followed by 30 cycles of 95°C for 1 min, 52°C for 1 min, and 72°C for 1 min followed by a final cycle of 72°C for 10 min. Samples were visualized by 5% polyacrylamide gel electrophoresis (PAGE) and quantified by the PhosphorImager (ImageQuant; Molecular Dynamics).
|
View this table: [in a new window] |
TABLE 1. RT-PCR primers
|
In vitro RNA synthesis.
32P-labeled RNA for the slot blot hybridization was synthesized using the T7 MEGAshortscript kit (Ambion). The ds cDNA from the antisense mRNA amplification (see above) was used as a template. The final concentration of rATP, rGTP, and rUTP was 5.6 mM, and the final concentration of unlabeled rCTP was 0.08 mM. Three microliters of [
-32P]rCTP (400 Ci/mmol) was used per reaction. The RNA was purified using an RNAeasy column (Qiagen), and 3.3 x 106 cpm of probe was used per slot blot.
Biotinylated RNA probe for the microarray hybridization was synthesized using a BioArray high-yield RNA transcript labeling kit (Enzo). The ds cDNA from the antisense mRNA amplification (see above) was used as a template. The RNA was purified, quantified, and fragmented according to Affymetrix protocols. Equal masses of probe (7 to 12 µg/microarray for three studies) were used for each set of microarrays.
4-thio-rUTP RNA probes for the cross-linking studies were synthesized as described previously (50). Two micrograms of EcoRI-linearized pSP6-(Trx2 or SAP49 or
-Globin)3'UTRpolyA (see below) and 1 µg of pTRI-ß-actin-mouse (which generates ß-actin antisense RNA) (Ambion) were used as template. The Maxiscript SP6 kit (Ambion) was utilized with final concentrations of rUTP (0.5 mM), rCTP (12 µM), and 4-thio-rUTP (0.25 mM) and 2.6 µl of [
-32P]rCTP (3,000 Ci/mmol). The RNA was purified using an RNAeasy column (Qiagen), and 1.5 x 106 cpm of RNA was used per reaction.
RNA probes for the electrophoretic mobility shift assay (EMSA) studies were generated using the Maxiscript SP6 kit (Ambion) with 1 µg of EcoRI-linearized pSP6-(Trx2 or SAP49 or
-Globin)3'UTRpolyA, 0.5 µg of pTRI-ß-actin-mouse (Ambion), with a rCTP (12 µM) and 5 µl of [
-32P]rCTP (400 Ci/mmol). RNA was purified (RNAeasy; Qiagen), and 7 x 105 to 9 x 105 cpm of RNA was used in each EMSA.
Slot blot hybridization.
Tenfold dilutions of plasmids (8 to 800 ng) containing the cDNAs encoding h
2-globin and ß-actin cDNA or PUC19 vector were diluted 100-fold in 0.4 M NaOH, transferred via slot blot vacuum manifold to Zetabind nylon (Cuno), and incubated in 0.4 M NaOH at room temperature for 5 min. The membrane was neutralized in 0.2x SSC (1x SSC is 150 mM NaCl and 15 mM sodium citrate)-0.2 M Tris (pH 7.5) at room temperature for 2 min and cross-linked in the UV Stratalinker 2400 (autocross-link) (Stratagene). The membrane was washed in 0.1x SSC-0.1% SDS at 65°C for 30 min and prehybridized in 0.5 M NaPO4 (pH 7.2), 7% SDS, 1% bovine serum albumin, and 0.1 mM EDTA at 65°C for 4 h. Then, 3.3 x 106 cpm was incubated with the membrane at 42°C overnight in a buffer of 5x SSC, 5x Denhardt's, 50% formamide and 1% SDS. After washing two times with 1x SSC-0.1% SDS at 42°C for 15 min and at 42°C for 30 min, the membranes were rinsed in 2x SSC and exposed to the PhosphorImager, and signals were quantified (ImageQuant; Molecular Dynamics).
Microarray hybridization and data analysis.
The biotinylated cRNAs were hybridized to the Affymetrix human genome U95A microarrays at the MIT biopolymers lab. For each set of microarray experiments, an equal mass of antisense RNA was used as the probe. The image ("dat") files were analyzed using Microarray Suite (MAS) version 5.0 (Affymetrix). A comparison analysis was performed between the experimental
CP2 microarray and the baseline control microarray for each experiment. The comparison files for each of three independent experiments were compiled into a single Excel file. This file was sorted to include those mRNAs that were designated "present" (i.e., detected) by MAS and those which showed an enrichment in the
CP2 microarray relative to the control microarray. The cutoff value for enrichment was twofold. The signal log ratio value, which reflects the abundance of an mRNA, was averaged among the three independent microarray experiments for each mRNA. This average signal log ratio was used to calculate the fold enrichment according to equations from Affymetrix. These fold enrichment values were normalized to the fold enrichment value calculated for the
-globin mRNA negative control. The individual normalized fold change (INFC) for each independent microarray experiment and the averaged normalized fold change (Avg NFC) for all three studies are represented in Table 2. The ranking of the mRNAs is based on the Avg NFC value.
|
View this table: [in a new window] |
TABLE 2. mRNAs (160) enriched in the CP2 immunoprecipitate relative to the control immunoprecipitate
|
-Globin 3'UTRpolyA has the same structure described above, except that it contains the 3'UTR of
2-globin mRNA. RNA binding studies. RNA EMSAs were carried out as described previously (6). UV cross-linking reactions were performed as described previously (50) with modifications. Thirty-five micrograms of the K562 extract was incubated in cross-linking buffer (8.5 mM HEPES [pH 7.4], 3.0 mM MgCl2, 27.0 mM KCl, and 1.0 mM DTT) with RNA (6 x 106 cpm; 90 nM) in the presence or absence of unlabeled competitor RNA. After irradiation and RNase digestion, the samples were immunoprecipitated with FF3 or control antibodies using the conditions described above for the RNP IP. The products were resolved by SDS-10% PAGE. Competition experiments were analyzed by the PhosphorImager and quantitated using ImageQuant (Molecular Dynamics).
|
|
|---|
CP-RNP IP:
-Globin mRNA interacts with
CP in vivo.
An
CP2-RNP IP strategy was established to isolate and identify a set of mRNAs that interact in vivo with
CP2 and its major splice variant form,
CP2-KL. The K562 cell line was chosen for this analysis. This human erythroid cell line contains high levels of human
-globin and
-globin mRNAs which can serve as positive and negative controls, respectively, for the IP reaction; interaction of
-globin mRNA with
CP2 has been previously characterized in detail and has a defined biologic function (23), while
-globin mRNA lacks
CP binding sites (49). Native
CP2-RNP complexes were immunoprecipitated from K562 cytoplasmic extracts using an affinity-purified rabbit antiserum specific to the two predominant human
CP isoforms,
CP2 and
CP2-KL (anti-
CP2) (6). As a specificity control, a parallel set of IPs (control IP) was carried out using an unrelated rabbit antiserum. Rabbit anti-human c-myc was used for this purpose. Parameters were established to maximize the yield and the specificity of
CP2-RNP complex IP (see Materials and Methods). To assess this approach, the relative contents of
-globin or
-globin mRNAs were compared in the RNA isolated from the anti-
CP2 IP and the control IP by targeted RT-PCR (Fig. 1A).
-Globin mRNA was enriched by 100-fold in the
CP2-RNP IP (lane 1) compared to the control IP (lane 2). In contrast, the contents of
-globin mRNA in the two preparations were within twofold of each other (lane 3 versus lane 4). As
-globin mRNA does not interact with
CP, this ratio of
-globin in the two preparations establishes the background ratio for comparisons of enrichment in each study (see below). These data demonstrate robust enrichment of
-globin mRNA in the
CP2-RNP complexes and establish in vivo association of
-globin mRNA with
CP2 in K562 cells.
![]() View larger version (40K): [in a new window] |
FIG. 1. Isolation of CP2-RNP complexes. (A) -Globin mRNA copurifies with CP2-RNPs isolated from human erythroid (K562) cells. Targeted RT-PCR was carried out on RNA isolated from RNP complexes immunoprecipitated with antiserum specific to the major CP2 isoforms, CP2 and CP2KL (anti- CP2) (lanes 1 and 3). Analysis of mRNAs isolated from a control IP reaction was carried out in parallel (control) (lanes 2 and 4). Lanes 1 and 2 are targeted amplifications of -globin mRNA, while lanes 3 and 4 are amplifications of -globin mRNA. The autoradiograph was intentionally overexposed to reveal trace levels of -globin mRNA present in the control lane (lane 2). The numbers on the left represent marker DNA fragments in base pairs. (B) Enriched representation of -globin mRNA in immunoprecipitated CP2-RNPs is maintained during probe amplification. cDNAs encoding actin, -globin, or pUC19 vector sequences were applied to a nylon membrane (8, 80, and 800 ng/slot; see Materials and Methods). The membranes were hybridized with 32P antisense probes generated from unamplified total cellular RNA (Total K562) and from amplified mRNA isolated from control or anti- CP2 IP reactions.
|
-Globin mRNA enrichment in the
CP2-RNP preparation is maintained during antisense probe amplification.
The optimized IP approach was applied to the identification of mRNAs present in
CP2-RNP complexes in K562 cells. To generate sufficient probe for a full set of microarray hybridizations, mRNAs copurified from each RNP preparation were cycled through an amplification protocol (see Materials and Methods). This protocol generates ds cDNAs that carry a T7 promoter. Subsequent in vitro transcription from this T7 promoter generates antisense probes complementary to the initial mRNA pools. To determine whether the representation of mRNAs in the
CP2-RNP complexes is maintained during the amplification procedure, radiolabeled antisense mRNA pools (see Materials and Methods) were used to probe a slot blot containing cDNAs encoding a set of control sequences:
-globin, ß-actin, or pUC19. ß-Actin represents an mRNA unassociated with
CP2, and pUC19 serves as a control for nonspecific hybridization. The results are shown in Fig. 1B. There was equivalent low-level hybridization to pUC19 sequences and to the ß-actin cDNA using probes derived from the anti-
CP2 and control IPs. In contrast,
-globin mRNA was enriched approximately 200-fold relative to the control IP and 55-fold relative to the unfractionated (total) K562 RNA pool. These data demonstrate that the amplification procedure maintains the enrichment of
-globin mRNA and support the validity of carrying out amplification of the RNAs prior to probe generation and microarray hybridization.
Microarray analysis of mRNA content in
CP2-RNPs isolated from K562 cells.
Amplified ds cDNAs from the IP reactions were used as templates to generate biotinylated antisense probes for interrogation of Affymetrix human genome U95A microarrays (12,600 open reading frames). A comparison analysis using Microarray Suite software, version 5.0, was performed for each experiment; the
CP2 IP microarray hybridization was designated the experimental microarray, and the control IP microarray hybridization was designated the baseline microarray (see Materials and Methods). Three independent studies were carried out, beginning each time with fresh extract and IP and proceeding through microarray hybridizations (Fig. 2). The total number of mRNAs detected on the microarrays varied by 1.6- to 2-fold among the three independent hybridizations, as did the number of mRNAs that were scored as enriched in
CP2-RNP complexes. Comparison among the data sets revealed a cohort of 160 mRNAs that copurified (i.e., were twofold or more enriched) with
CP2-RNP complexes in all three experiments. These mRNAs were considered a maximally reliable set of in vivo
CP2-binding targets.
![]() View larger version (17K): [in a new window] |
FIG. 2. Summary of three independent microarray analyses of CP2-associated mRNAs. Three independent studies were carried out to identify mRNAs associated with cytosolic CP2-RNPs isolated from K562 cells. The total number of mRNAs detected in the CP2-RNP IPs and the number of mRNAs enriched in each of the CP2-RNP IPs (relative to the control IP) are shown. The percentages represent the quotient of identified mRNAs to total mRNAs represented on the microarray. The number of mRNAs that were enriched in all three microarray surveys is indicated in the lower box. These consistently detected mRNAs are individually listed in Table 2.
|
CP2-RNPs.
The 160 mRNAs that copurified with
CP2 in all three IP studies are displayed in Table 2. Each mRNA is identified by its Affymetrix identification number (Probeset I.D.), GenBank accession number, Avg NFC, and its rank in the enrichment profile (see Materials and Methods for determination of the Avg NFC and rank values). The Avg NFC ranged from 5 to 80. The INFC is also shown. Each mRNA was individually annotated by a database search, and the entire cohort of mRNAs was then organized into a series of subsets according to documented or putative functions. The functional assignments should be considered dynamic because several proteins have multiple functions and could have been assigned to alternative groups. Groups with more than three mRNAs are summarized in Fig. 3. These grouped mRNAs represent 50% of the full list of 160 mRNAs (see Table 2).
![]() View larger version (27K): [in a new window] |
FIG. 3. Major groupings of mRNAs enriched in the CP2-RNP complexes. The number in parentheses below each category represents the number of mRNAs identified in the group. Note that CP2 and NF B are both represented twice on the microarray (see Table 2) but are counted only once in the grouping shown here.
|
CP2-RNP enriched mRNA population, and of the 160 most abundant mRNAs observed in amplified total K562 RNA, only 6 were present on the list of
CP2-interacting mRNAs. Furthermore, inspection of the sequences of many of the 160 mRNAs revealed several potential
CP binding sites, defined as C- or CU-rich sequences (see above). The presence of
-globin mRNA in the
CP2-RNP mRNA cohort (rank no. 3) supports the validity of the IP-microarray screen. The mRNA with the greatest enrichment (80-fold) in the
CP2-RNP complexes encoded spliceosomal-associated protein 62 kDa (SAP62). Interestingly, another mRNA encoding a spliceosome-associated protein, SAP49, also ranked high on the list, at no. 20. Of note,
CP2 mRNA was present in this list as well; two distinct probe sets on the microarray represent
CP2, and both were enriched in the
CP2-RNP complexes, ranking at nos. 69 and 83. The mRNA encoding mitochondrial thioredoxin (Trx2) ranked at no. 60, and along with 5 other mRNAs, formed a group of mitochondrial enzymes. Of note, we specifically screened the list of 160
CP2-RNP-associated mRNAs for mRNAs that have been previously proposed as
CP binding targets; only
-globin was found to be in common (see Discussion).
Confirmation of in vivo
CP2-RNP associations by targeted mRNA analysis.
Ten mRNAs identified as enriched in the
CP2-RNP complexes by the microarray analysis were chosen for confirmatory studies. Anti-
CP2 or control IP reactions were carried out using fresh K562 extracts, and the copurified mRNAs were directly assayed without prior amplification (Fig. 4). The candidate mRNAs included
-globin, SAP62, SAP49, Trx2,
CP2, c-src, junD, a-raf-1, Cln2, and PPT2. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
-globin mRNAs were assayed in parallel as negative controls. In each assay, the
-globin mRNA demonstrated robust enrichment in the
CP2-RNP population relative to the control IP (Fig. 4A to E, lanes 1 and 2, respectively). Each of the 10 mRNAs identified as enriched in
CP2-RNPs when assayed by microarray hybridization was confirmed to be enriched when independently assayed by targeted RT-PCR analysis of
CP2-RNP preparations. These 10 mRNAs encode SAP49 and Trx2 (Fig. 4A);
CP2,
CP2-KL, and SAP62 (Fig. 4B); the proto-oncoproteins c-src, junD, and a-raf-1 (Fig. 4C); and 2 mRNAs which encode factors linked to infantile neuronal ceroid lipofuscinosis, namely, Cln2 and PPT2 (15, 42) (Fig. 4D). CoxII was also tested for interaction with
CP2 by targeted RT-PCR (Fig. 4E). Even though it is not present on the microarray used in these studies, we wanted to assess whether this mRNA interacts with
CP2 because it has been shown previously to be a binding partner of
CP1 (49). Figure 4E shows that coxII mRNA is robustly associated with
CP2-RNPs. eIF3b mRNA was included in one of the studies as an example of an additional sequence on the microarray that was not enriched for in the
CP2-RNPs. Consistent with the microarray screen, the targeted analysis failed to demonstrate enrichment of this mRNA (data not shown). Taken together, the studies confirm the accuracy of the microarray screen for
CP2-associated mRNAs.
![]() View larger version (65K): [in a new window] |
FIG. 4. Confirmation of microarray detection of mRNA enrichment in CP2-RNP complexes by targeted analysis. Each of the mRNAs noted above the lanes was semiquantitatively assessed by RT-PCR of RNPs isolated with anti- CP2 or control antisera. In each of the four studies, analysis of -globin mRNA and -globin mRNAs were included as positive and negative controls, respectively. Numbers on the left represent the migration of marker DNA fragments. (A) Analysis of SAP49, Trx2, and GAPDH mRNAs. In this study, GAPDH was included as an additional negative control. (B) Analysis of CP2 and SAP62 mRNAs. The amplification of the CP2 mRNA reveals two major bands representing mRNAs encoding CP2 and CP2-KL. (C) Analysis of three proto-oncoprotein-encoding mRNAs, c-src, junD, and a-raf-1. (D) Analysis of two mRNAs associated with infantile neuronal ceroid lipofuscinosis, Cln2 and PPT2. (E) Analysis of coxII mRNA.
|
CP2 binding sites.
SAP49 and Trx2 mRNAs were chosen as representatives for further analysis of
CP2 interactions. The specific question was whether the noted in vivo association of these mRNAs with
CP2-RNPs reflected direct binding by
CP2. The focus on 3' UTR interactions was based on the precedent of documented functional interactions between
CPs and 3' UTRs of other cellular mRNAs (see above). In cases where
CP binding sites have been defined, they contain short patches of C- or CU-rich sequences (2, 12, 35, 36, 38, 45, 52, 53) that are sometimes repeated multiple times (35). Examination of the 3' UTR of SAP49 reveals 12 potential
CP binding sites defined as a stretch of C's or U's of more than five nucleotides. The Trx2 3' UTR also contains several CU-rich regions, including four CCCUUCC and three CCUCC repeats that are potential
CP binding sites. The ability of the 3' UTRs of SAP49 and Trx2 to bind cytoplasmic proteins derived from K562 cells was tested in vitro by EMSA. The 3' UTR of
-globin mRNA and an actin ß-antisense transcript were included as positive and negative controls, respectively (Fig. 5A). The 3' UTR of SAP49 formed three complexes (designated A, B, and C) with the K562 extract. The Trx2 and
-globin 3' UTRs each formed two complexes (designated A and C) with the K562 extract. Complexes A and C were of similar sizes for the three probes (compare lanes 4, 6, and 8) and were specifically absent in the actin antisense RNA incubation (lane 2). Homoribopolymer competition was performed to further test for the presence of
CP in the SAP49 3' UTR complexes (Fig. 5B). Unlabeled poly(C) competed efficiently and selectively for the fastest complex (complex A) (compare lane 2 with lanes 3 to 5), completely competing even at the lowest concentration of poly(C) tested (10-fold molar excess over the UTR probe [lane 3]). Of note, the migration position of complex A is identical to the previously characterized
-complex formed between
CP and
-globin mRNA (6). In contrast, the other three homoribopolymers had less pronounced effects (lanes 6 to 14). The selective and marked sensitivity of complex A to poly(C) supports the conclusion that the SAP49 3' UTR can directly bind
CP (for further evidence, see below).
![]() View larger version (43K): [in a new window] |
FIG. 5. The 3' UTRs of SAP49 and Trx2 mRNAs bind directly and specifically to CP2. (A) RNA EMSA analysis. 32P-labeled RNAs corresponding to the four RNAs indicated at the top of the figure were incubated with K562 extract (Probe + Extract) or without K562 extract ([32P]UTR Probes) as indicated. Three observed RNP complexes are referred to as A, B, or C. ß-Actin antisense (ActAS) and -globin RNAs served as negative and positive controls, respectively. (B) EMSA analysis of the SAP49 3' UTR in the presence of unlabeled homoribopolymer competitors. Triangles represent increasing amounts of competitor RNA used in the EMSA (10-, 100-, and 500-fold molar excess over the labeled probe). The competitor utilized is indicated above the triangles. (C) UV cross-linking of cytoplasmic proteins to RNA sequences. The same four RNA sequences analyzed by EMSA in Fig. 5A were UV cross-linked to K562 extract and immunoprecipitated with anti- CP2 or control sera. Numbers on the left represent the migration of marker proteins. The arrows to the right of the autoradiograph indicate the cross-linked products representing CP2 and CP2-KL.
|
CP2.
UV cross-linking studies were carried out to substantiate a direct interaction of
CP2 with the 3' UTRs of
CP2-RNP-enriched mRNAs. Radiolabeled and thiolated 3' UTRs corresponding to the SAP49 or Trx2 3' UTRs were UV cross-linked to K562 extract. The 3' UTR of
-globin mRNA and a ß-actin antisense transcript were labeled and analyzed in parallel as positive and negative controls, respectively. When the cross-linked products were analyzed by SDS-PAGE, four prominently labeled bands were generated (data not shown). These products appeared to represent nonspecific interactions based on the uniform patterns with the four transcripts and their sensitivity to competition by 18S rRNA. To visualize less abundant complexes that might represent
CP2 binding, the cross-linked products were immunoprecipitated with anti-
CP2 or control antisera (Fig. 5C). Two immunoprecipitated cross-linked products were observed with anti-
CP2 antisera, a 38-kDa band and a less intense 36-kDa band that is seen more clearly on longer exposures (data not shown). These two products (double arrow to the right of the gel) correspond to the sizes of the two major
CP2 isoforms,
CP2 and
CP2-KL. These complexes were detected only when the
-globin, SAP49, and Trx2 3' UTRs were used as probes in the cross-linking (lanes 4, 6, and 8); no immunoprecipitated cross-linked products were observed using the ß-actin antisense RNA (lanes 1 and 2). A series of cross-competition experiments using the 3' UTRs of Trx2 or SAP49 and human 18S rRNA confirmed that
CP2 specifically interacted with the Trx2 and SAP49 3' UTRs (data not shown). These studies support the conclusion that
CP2 can directly and specifically bind to the 3' UTRs of SAP49 and Trx2 mRNAs. |
|
|---|
CP2 and
CP2-KL proteins (referred to collectively as
CP2) encoded at the PCBP-2 locus. Three independent analyses of the
CP2-RNPs reveal a consistent cohort of 160 mRNAs (Table 2). With the exception of
-globin mRNA, these mRNAs represent novel targets of
CP2 interaction. How
CP2-containing complexes factor into posttranscriptional controls and to what extent such controls might coordinate the expression of subgroups of these mRNAs are questions now open to study.
Several technical aspects and limitations of this approach need to be emphasized. First, the isolation of the
CP2-RNPs depends on IP. It is possible that additional
CP2-RNP complexes are present in the cell but are not recognized in this procedure due to constraints on protein accessibility and/or subsequent precipitation. Thus, the set of mRNAs identified in this study, while extensive, may not encompass all
CP2-mRNPs. Second, the U95A microarray used in this study contains 12,600 probe sets representing approximately 10,500 unique mRNAs. As current estimates of the number of structural genes in the human genome is in the range of 25,000 or more (28), it is possible that additional targets might be found on subsequent studies using more extensive arrays. Third, the present analysis was limited to cytosolic complexes. The possibility that
CP2 binds to additional transcripts in the nucleus is not presently addressed. Fourth, mRNA sequences from the immunoprecipitated RNPs were amplified in order to generate sufficient probe to interrogate a full microarray. While such a step might alter the representation or abundance of sequences in the population, the validity of utilizing amplified RNA probes is supported by prior reports (40) and was confirmed by a series of control experiments (Fig. 1). Finally, only mRNAs that were enriched (twofold or more) in all three studies were included in the compilation (Table 2). This represents a conservative cutoff. Thus, the 160 mRNAs identified in this report should be considered a reliable but not comprehensive representation of K562 mRNAs present in
CP2-RNP complexes.
It is recognized that the protein contents of the
CP2-RNP complexes are unlikely to be homogeneous in composition. Instead, some of these complexes may contain full-length
CP2, while others may contain the alternative-splice isoform,
CP2-KL. These differences in
CP isoform content may mediate distinct sets of protein-protein interactions, generating diverse macromolecular complexes with distinct functions.
CP2 may also be subject to posttranslational modifications that may regulate the function and/or composition of the complexes (24). Finally, the particular mRNA content of the complexes may dictate the protein composition of the RNP complex via allosteric effects on the binding protein, as has been established for certain protein-DNA interactions (42, 47).
Individual mRNAs identified in the
CP2-RNP complexes may be directly bound by
CP2, or alternatively, their association with
CP2 may be indirect. In the case of human
-globin mRNA,
CP is known to bind directly and uniquely to the C-rich motifs within the 3' UTR (19). However, it is possible that mRNAs identified in the present survey may be bound by distinct subsets of proteins that are coprecipitated with
CP2 as part of macromolecular
CP2-RNP complexes (22). In the limited sampling of the novel mRNAs associated with the
CP2-RNPs, direct interaction of the mRNA with
CP2 does, in fact, appear to be occurring (Fig. 5). Thus, for at least two of the novel
CP2 mRNPs identified in this study, the specific mRNA inclusion (Trx2 and SAP49) in the complex appears to reflect direct binding by
CP2 as determined for
-globin mRNA.
It is significant that
-globin mRNA was identified in the present screen of
CP2-RNPs and that it constituted the third-most enriched mRNA (Table 2). In contrast,
-globin mRNA, which is as abundant as
-globin mRNA in K562 cells, was not present in the enriched pool of mRNAs. This selective detection of
-globin mRNA supports the validity of the approach and confirms the association of
-globin mRNA with these complexes in the cell.
Prior to this study, 14 cellular mRNAs had been reported as targets for
CP interaction (see above). Only two of these mRNAs,
-globin and coxII, were identified in the present study. There are multiple reasons for the absence of the remaining mRNAs. mRNAs encoding
I(I) collagen, tyrosine hydroxylase, androgen receptor, 15-lipoxygenase mRNA, PP 2A
, folate receptor
, and erythropoietin are represented on the microarray but were not detected by analysis of total K562 mRNA and thus are probably not present in these cells. Likewise, c/EBP
mRNA, which is not represented on the microarray, could not be detected by targeted RT-PCR of total K562 mRNA (data not shown), consistent with a previous study which showed that this mRNA is not present in K562 cells (41). In contrast, TAPA-1 mRNA (see above) is detected in microarray analysis of total K562 RNA but is not enriched in the immunopurified
CP2-RNPs. This may reflect the fact that TAPA-1 was identified as a target of
CP1 by prior studies and may be specific to this isoform (49).
Coordination of posttranscriptional controls by particular RNA-binding proteins may occur at a number of steps. We have previously suggested that the
-complex may constitute a common determinant of high-level stability (18). The identification in the present survey of 160 mRNA targets of
CP2 can now be used to further test this premise. Fourteen of these mRNAs encode structural cytoskeletal components or proteins involved with cell motility. It is likely that these are long-lived mRNAs based on the premise that proteins that do not need to be acutely controlled are usually encoded by highly stable mRNAs (45). A second well-defined function of
CP is in translation control. Identifying whether any of the 160 cellular mRNAs are subject to this level of control would establish another provisional basis for potential coordination of gene expression by
CP2-RNP complexes.
mRNAs encoding 11 enzymes were present in the
CP2-RNP population. Two of these enzymes are linked to the pathogenesis of the neurodegenerative disorder infantile neuronal ceroid lipofuscinosis (15, 43). The identification of these two enzymes, lysosomal pepstatin-insensitive protease (Cln2) (rank no. 54) and palmitoyl-protein thioesterase 2 (PPT2) (rank no. 103), suggests that
CP2 might act as a modifier of phenotype in this disease by regulating the available levels of these two enzymes in a coordinate manner. It is also of note that 6 of the 20 total enzyme-encoding mRNAs in the
CP2-RNP population direct the synthesis of enzymes specific to the mitochondria. Two of the six mRNAs identified in an independent screen for
CP1-associated mRNAs also encoded mitochondrial localized proteins (49). These data suggest that
CPs may coordinate aspects of mitochondrial function or mRNA localization via posttranscriptional mechanisms.
Thirteen
CP2-associated mRNAs encode transcription factors. The potential involvement of
CP2 in transcription factor expression is consistent with a report showing that
CP2 regulates translation of the mRNA encoding the transcription factor, c/EBP
(39). It is also of interest that JunD mRNA is enriched in the
CP2-RNPs. Expression of JunD is regulated at the posttranscriptional level (27) by alterations in mRNA stability in response to cellular levels of polyamines. The association of
CP2 with JunD mRNA in the present study establishes a testable model in which
CP2 may play a role in this process. Thus, both translation and stability controls may be in play via
CP2 association with transcription factor mRNAs.
The presence of four mRNAs encoding interferon-inducible factors in the
CP2 RNPs is intriguing, as five different viruses have been reported to utilize
CP to regulate viral gene expression (see above). Since interferon is an antiviral agent, it is possible that these viruses have evolved structures that allow them to sequester
CP2 from these cellular mRNAs. For example, if
CP2 enhances the expression of specific interferon-inducible genes, sequestration of
CP2 by viral RNAs would inhibit the antiviral response while at the same time possibly enhancing their own expression (3, 4, 11, 12, 33, 51). The demonstration that expression of RNA decoys can block the functional interaction of
CPs with target RNAs in vivo supports several assumptions underlying this model (30).
A final note concerns
CP2 mRNA. The enrichment of
CP2 mRNA in
CP2-RNP complexes was confirmed by two separate probe sets on the microarray (Table 2) and substantiated by directed RT-PCR analysis (Fig. 4B). This association suggests that
CP2 expression may be subject to posttranscriptional autoregulation. A negative autoregulatory loop might mediate tight control over synthesis of the final
CP2 product, while a positive loop might amplify the expression of
CP2 in certain situations. Further mapping of this interaction and the corresponding mechanistic pathway(s) involved in the proposed autoregulation of
CP2 expression are of interest for further study.
We thank Gregg Johannes for critical reading of the manuscript and experimental advice.
|
|
|---|
-globin mRNA stability complex reflects binary interaction between the pyrimidine-rich 3' untranslated region determinant and poly(C) binding protein
CP. Mol. Cell. Biol. 19:4572-4581.
CP with actively translating mRNAs. Mol. Cell. Biol. 23:899-907.
-globin mRNA stability complex. Mol. Cell. Biol. 17:4870-4876.
-globin mRNP stability complex. EMBO J. 14:4357-4364.[Medline]
is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell. Biol. 18:4301-4314.
1(I) mRNA in hepatic stellate cells. Mol. Cell. Biol. 17:5201-5209.
-globin mRNA stability. Mol. Cell. Biol. 15:1769-1777.
2-globin 3' nontranslated region. Mol. Cell. Biol. 15:2457-2465.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»